Ceva inks pheromone R&D deal with local partner

Jun 14, 2016

As it pushes toward its goal of being a top 5 animal health player by 2020, Ceva Animal Health has signed a pheromone R&D pact with insect repellant specialist M2i Life Sciences. The 10-year arrangement between the two companies will center around the development of “formulations and innovative systems” to utilize pheromones in animal health, according to a press release. M2i is a top player in pheromone applications for agriculture, according to the release. Ceva is already a player in pheromone products with Feliway and Adaptil to treat behavior issues in cats and dogs, respectively. The products are synthetic version of pheromones, which are naturally-occurring molecules suspected to have a calming impact on animals. As of 2014, Ceva’s pheromone-based products were supported by 42 clinical studies, the company’s website says. For Ceva, the partnership comes in quick succession after its deal last week to buy France’s Biovac. Through that purchase, Ceva picked up Biovac’s “autogeneous” vaccine technology and allergy treatment offerings. Overall, the moves are part of a larger effort by Ceva to compete... ...

Read More

Aratana details pivotal data on Entyce appetite drug for dogs

Jun 14, 2016

As any pet owner can attest, when a dog stops eating it can be a source of major concern. With its recently approved product for dogs, Entyce, Aratana Therapeutics ($PETX) hopes to create a new market–a pharmaceutical approach to coaxing canines back to their food bowls. Towards that end, the company is offering details about what happened during the pivotal clinical trial for Entyce (capromorelin), which is liquid solution that mimics ghrelin, a hormone which sparks the feeling of hunger. On June 10, Aratana presented the data at the American College of Veterinary Internal Medicine (ACVIM) forum in Denver. During the trial, which involved 244 pet dogs, 68.6% of pets taking Entyce experienced improvements in appetite, their owners reported. By comparison, just 44.6% of dogs taking a placebo improved. And 56.2% of the dogs on Entyce exhibited improvements in appetite-related behaviors, such as anticipating mealtime, eating with enthusiasm and actively seeking out food even when it’s not readily available. Just 26.8% of dogs on the placebo showed similar behaviors. The drug was tried... ...

Read More

Nutriad introduces MYCOMAN®: mobile app for mycotoxin management

Jun 13, 2016

Mycotoxins in cereal crops affect the health and performance of animals all around the world. Changing quality and availability of raw materials lead to an increasing need for efficient ways of measuring the level of mycotoxin contamination, allowing producers to respond quickly. Multinational feed additives producer Nutriad launches an innovative app to support producers in making the right decisions as far as mycotoxin management is concerned. Various systems for rapid detection of different mycotoxins are commercially available. All of them are suitable for quick and sensitive screening of raw materials before they enter the feed mill. Once mycotoxins levels are evaluated in all ingredients, contamination level of feed can be estimated. This allows the precise calculation of mycotoxin deactivator or binder needed.  States Nutriad CEO Erik Visser: “The benefits of rapid screening methods are generally lower costs, faster results, less technical requirements, portability and more rapid throughput of large numbers of samples. Whilst these rapid techniques allow for good analyses, most of them are specific for one certain mycotoxin only... ...

Read More

Alltech acquires Coppens International, an innovative aquatic feed and nutrition company

Jun 7, 2016

Establishes a dynamic aquatic feed solutions provider combining innovation, technology, research and development to deliver value and efficiency to aquatic farmers around the world   Union will accelerate aquatic feed innovation through combined scientific knowledge, technology, research and development [DUNBOYNE, Ireland] – Alltech has acquired Coppens International, a leading international aquatic feed solutions company in the Netherlands. Coppens International is now part of the Alltech family of companies, which includes 14 other companies that Alltech has acquired globally since 2011. For almost 24 years, Coppens International has earned a strong reputation for being an innovative, high-quality aquatic feed producer. The company’s specialties include temperate and tropical marine and freshwater diets for a variety of juvenile and adult species. The company also produces top-quality ornamental, specialty and bait feeds. Alltech’s latest acquisition enhances the Coppens International product range by integrating Alltech’s microalgae and protein platforms, thereby providing customers with cutting-edge sustainable technologies pertinent to success in today’s demanding aquaculture industry. Always thinking ahead, Alltech already owns one of the world’s largest... ...

Read More

Bayer and BioNTech Join Forces to Develop Innovative New mRNA Vaccines and Therapeutics for Animal Health Applications

Jun 7, 2016

Leverkusen / Mainz, Germany, May 10, 2016 – Bayer and BioNTech AG, a leading immunotherapy company headquartered in Mainz, Germany have entered into an agreement to develop novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications. BioNTech will contribute its proprietary mRNA technology platform, formulation development capabilities, immunology expertise and intellectual property, while Bayer’s Animal Health unit will provide its development expertise and disease know-how. This is the first partnership of its kind making a substantial investment in mRNA therapeutics specifically for Animal Health applications. More at: http://press.bayer.com/baynews/baynews.nsf/id/Bayer-BioNTech-Join-Forces-Develop-Innovative-New-mRNA-Vaccines-Therapeutics-Animal-Health?Open&parent=news-overview-category-search-en&ccm=020 ...

Read More

Bayer and Université de Sherbrooke Enter License Agreement to Drive Innovation in Dairy Cattle Health

Jun 7, 2016

Strategic licensing transaction focuses on advancing a novel vaccine candidate for mastitis, one of the most challenging endemic diseases affecting dairy herds   Leverkusen, Germany, and Quebec, Canada, May 30, 2016 – Bayer and TransferTech Sherbrooke, the corporate entity responsible for commercializing the innovations emerging from the Université de Sherbrooke and its affiliated institutions, have signed a global license agreement to advance a novel vaccine candidate discovered at Université de Sherbrooke in Quebec, Canada, to help protect dairy cattle from mastitis caused by the bacterium Staphylococcus aureus. More at: http://press.bayer.com/baynews/baynews.nsf/id/Bayer-Universit-Sherbrooke-Enter-License-Agreement-Drive-Innovation-Dairy-Cattle-Health?Open&parent=news-overview-category-search-en&ccm=020 ...

Read More

Vaccine BioProcessing Seminar

May 25, 2016

One of VacciXcell’s main visions is a world of vaccine self-sufficiency for all nations, including developing ones and conducting free end-user seminars is one of VacciXcell’s ways to fulfil this vision. These end-user seminars help increase awareness of current news and situations in the vaccine industry and as well as the latest trends and techniques in vaccine bioprocessing; moreover VacciXcell’s end-user seminars could be about general vaccine bioprocessing or focused particularly on animal or human vaccine bioprocessing. One of the highlights in VacciXcell’s vaccine bioprocessing seminars are VacciXcell’s tide motion system, which is an ideal platform for the research and production of vaccines both for human and animal use for its high productivity, low production cost, and true linear scalability. ...

Read More

Activist investor Ackman to sell $800M worth of Zoetis shares: Report

May 18, 2016

Just days after Zoetis ($ZTS) announced better-than-expected results in its first quarter, the activist investor who once told the company to shape up or sell itself–William Ackman of Pershing Square Capital–seems to be backing off of the animal health giant. On May 9, Pershing planned to sell 16.85 million shares of the company for about $800 million, according to anonymous sources who spoke to the New York Times. Zoetis’ shares have risen 8.6% since Pershing Square bought up 8.5% of the company for $1.5 billion in late 2014. The hedge fund will still own 25 million shares after the transaction, which will be managed by Bank of America Merill Lynch and Credit Suisse, according to the Times. But Pershing Square’s William Doyle, who joined Zoetis’ board last year, will be stepping down this week. Pershing Square was instrumental in getting Zoetis CEO Juan Ramón Alaix and his management team to focus on improving the company’s bottom line. During Zoetis’ first-ever Investor Day in New York in November 2014, Ackman reportedly... ...

Read More

NUTRIAD WITH STRONG PRESENCE AT APA CONVENTION

May 18, 2016

The 2016 APA convention (Asia Pacific Aquaculture) took place in Surabaya from 26th till 29th of April, and surely was the major aquaculture exhibition in South East Asia this year, attracting close to 5,000 participants. The massive presence of Indonesian aquaculturists, including farmers, governmental staff and researchers proved the importance of the aquaculture community in Indonesia.  Indonesian aquaculture grew nearly 20% in the last 5 years in hectares in production and over 50% per year in volume produced over the last 10 years.   “Attendees from all over South East Asia learned how the Indonesian aquaculture industry managed to realize this amazing growth and the conference was very well attended with participants,” said Allen Wu, Nutriad’s Regional Manager Aquaculture APAC, and Board Director of the organizing World Aquaculture Society – Asia Pacific Chapter. The International Symposium on Tilapia in Aquaculture (ISTA) was part of the program. Furthermore, a special producer program for Indonesian aquaculture producers, IndoAqua, Fita and the 12th All Indonesian Young Koi Show were incorporated in this event.... ...

Read More

Aratana Q1 loss widens amid shift towards commercial enterprise

May 11, 2016

One week after announcing a commercial partnership with Eli Lilly’s ($LLY) Elanco, Aratana ($PETX) CEO Steven St. Peter remained upbeat about the deal, even as his company reported first-quarter earnings that fell short of expectations. After the market closed on May 5, the Kansas-based company announced that its revenues in the quarter came in at $172,000 and its net loss doubled year-over-year to $18.1 million (52 cents a share). Analysts had expected the loss to be 42 cents, according to Zacks Investment Research. Aratana is preparing to launch its first major product, Galliprant (grapiprant), to treat osteoarthritis (OA) pain in dogs. The Elanco deal netted Aratana an upfront payment of $45 million and the potential for milestone payouts. In return, Elanco has exclusive rights to market the drug overseas, as the two companies co-promote it in the U.S. Aratana filed for approval of Galliprant in Europe in February and anticipates launching the drug there in 2017. The Elanco alliance will allow Aratana to leverage the marketing expertise and sales presence of... ...

Read More